Moderna ’ s mRNA Skin Cancer Vaccine Shows Early Promise in a New Study
Coming off the success of its mRNA vaccine for COVID-19, Moderna announced on Dec. 13 that it achieved encouraging results when it turned its vaccine technology against cancer.
The company reported in a release that among 157 people with stage 3 or stage 4 melanoma, a personalized cancer vaccine that Moderna developed with Merck—created using mRNA genetic material from each patient’s respective tumors—reduced the risk of recurrence or death by 44% compared to standard care.
“For the first time ever, we have evidence that it’s possible to develop a functional immune response that can treat pati...
Source: TIME: Health - December 13, 2022 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Cancer COVID-19 Source Type: news
'New paradigm' moment as mRNA cancer vaccine slashes risk of tumor relapse or death
Pharma giants Merck and Moderna which developed the shot today heralded the results as 'spectacular' and a 'tremendous step forward'. It targets high-risk melanoma. (Source: the Mail online | Health)
Source: the Mail online | Health - December 13, 2022 Category: Consumer Health News Source Type: news
mRNA Cancer Vaccine Shows Promise; Sounding the Strep A Alarm; Phasing Out Tobacco
(MedPage Today) -- Note that some links may require subscriptions.
Moderna said its investigational personalized mRNA cancer vaccine, combined with pembrolizumab (Keytruda), cut the risk of melanoma recurrence or death compared with pembrolizumab... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - December 13, 2022 Category: Dermatology Source Type: news
Real-World Study Shows Patients Treated with IMBRUVICA ® (ibrutinib) Were Less Likely to Initiate a Next-Line Treatment than Patients on Acalabrutinib in First-line Chronic Lymphocytic Leukemia
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results of a real-world study showing that patients with chronic lymphocytic leukemia (CLL) treated with first-line acalabrutinib monotherapy were 89 percent more likely to start a next-line treatment than those treated with IMBRUVICA® (ibrutinib).[1] These data suggest the potential that first-line treatment with IMBRUVICA® in routine practice may provide patients with the ability to use once-daily, all-oral IMBRUVICA® as a monotherapy treatment for a longer period without the need to start the next line of ...
Source: Johnson and Johnson - December 12, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA ® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated Chronic Lymphocytic Leukemia
NEW ORLEANS, December 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new four-year follow-up results from the Phase 3 GLOW study (Abstract #93), which showed investigational, fixed-duration treatment with IMBRUVICA® + venetoclax (I+V) reduced the risk of progression or death by 79 percent among older and/or unfit patients with previously untreated chronic lymphocytic leukemia (CLL) compared to patients treated with chemoimmunotherapy.[i] These results were highlighted in an oral presentation during the 2022 American Society of Hematology (ASH) Annual Meeting.1CLL is the most com...
Source: Johnson and Johnson - December 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
